RU2012124232A - PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES - Google Patents
PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES Download PDFInfo
- Publication number
- RU2012124232A RU2012124232A RU2012124232/15A RU2012124232A RU2012124232A RU 2012124232 A RU2012124232 A RU 2012124232A RU 2012124232/15 A RU2012124232/15 A RU 2012124232/15A RU 2012124232 A RU2012124232 A RU 2012124232A RU 2012124232 A RU2012124232 A RU 2012124232A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- treatment
- diseases
- demielinization
- autoimmune demyelinating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 9
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 6
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract 4
- 230000001363 autoimmune Effects 0.000 claims abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 3
- 229920002472 Starch Polymers 0.000 claims abstract 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims abstract 3
- 235000013539 calcium stearate Nutrition 0.000 claims abstract 3
- 239000008116 calcium stearate Substances 0.000 claims abstract 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims abstract 3
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000011734 sodium Substances 0.000 claims abstract 3
- 229910052708 sodium Inorganic materials 0.000 claims abstract 3
- 235000019698 starch Nutrition 0.000 claims abstract 3
- 239000008107 starch Substances 0.000 claims abstract 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 229940075993 receptor modulator Drugs 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтическая композиция в виде таблеток, содержащая модулятор рецептора S1P, представляющий собой 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол и/или его фармацевтически приемлемую соль и вспомогательные вещества, отличающаяся тем, что содержит в качестве вспомогательных веществ микрокристаллическую целлюлозу, карбоксиметилкрахмал натрия, стеарат кальция или стеарат магния, при следующем содержании компонентов, г:2. Фармацевтическая композиция по п.1, отличающаяся тем, что фармацевтическая композиция пригодна для лечения аутоиммунных демиелинизирующих заболеваний.3. Фармацевтическая композиция по п.2, отличающаяся тем, что аутоиммунным демиелинизирующим заболеванием является Рассеянный склероз (MS).1. A pharmaceutical composition in the form of tablets containing an S1P receptor modulator, which is 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol and / or its pharmaceutically acceptable salt and excipients, characterized the fact that it contains microcrystalline cellulose, sodium carboxymethyl starch, calcium stearate or magnesium stearate as auxiliary substances, with the following content of components, g: 2. The pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition is suitable for the treatment of autoimmune demyelinating diseases. The pharmaceutical composition of claim 2, wherein the autoimmune demyelinating disease is Multiple Sclerosis (MS).
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012124232/15A RU2506949C1 (en) | 2012-06-13 | 2012-06-13 | Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases |
| PCT/RU2013/000053 WO2013187795A1 (en) | 2012-06-13 | 2013-01-25 | Pharmaceutical composition of an s1p receptor agonist for treating demyelinized disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012124232/15A RU2506949C1 (en) | 2012-06-13 | 2012-06-13 | Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012124232A true RU2012124232A (en) | 2013-12-20 |
| RU2506949C1 RU2506949C1 (en) | 2014-02-20 |
Family
ID=49758513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012124232/15A RU2506949C1 (en) | 2012-06-13 | 2012-06-13 | Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2506949C1 (en) |
| WO (1) | WO2013187795A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2577230C1 (en) * | 2015-04-09 | 2016-03-10 | Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" | Method of producing capsules of fingolimod hydrochloride |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1613288B1 (en) * | 2003-04-08 | 2008-11-19 | Novartis AG | Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol |
| GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| CA2925175A1 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
-
2012
- 2012-06-13 RU RU2012124232/15A patent/RU2506949C1/en active
-
2013
- 2013-01-25 WO PCT/RU2013/000053 patent/WO2013187795A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| RU2506949C1 (en) | 2014-02-20 |
| WO2013187795A1 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017109139A (en) | TABLETS CONTAINING A BIG DOSE OF RUKAPARIBA | |
| RU2016122609A (en) | COMPOSITIONS OF AZAINDOL COMPOUNDS | |
| JP2015091822A5 (en) | ||
| RU2012142811A (en) | PHARMACEUTICAL COMPOSITIONS AND ORAL ORAL DOSED FORMS OF LEVERODOPE'S MEDICINAL PRODUCTS AND METHODS OF APPLICATION | |
| EA201590520A1 (en) | PHARMACEUTICAL COMPOSITION WITH COATING CONTAINING REGORAPHENIB | |
| RU2014138035A (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 1- (3- (2- (1-BENZOTIOPHEN-5-IL) ETHOXY) PROPYL) AZETIDIN-3-OL OR ITS SALT | |
| AR100977A1 (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION | |
| RU2012124232A (en) | PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES | |
| RU2013126056A (en) | COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) | |
| RU2008115582A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | |
| RU2013130801A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES OF JOINT AND BONE TISSUES | |
| RU2011121388A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS | |
| HRP20171930T1 (en) | Diazonamide analogs | |
| RU2010134123A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALLERGIC DISEASES | |
| RU2009114885A (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID ORAL DRUG FORM FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT | |
| RU2010129867A (en) | ANTIVIRAL AGENT IN TABLETS AND METHOD FOR PRODUCING IT | |
| RU2017112352A (en) | SOLID MEDICINAL FORM INDOL-3-CARBINOL | |
| RU2013157797A (en) | PHARMACEUTICAL COMPOSITION FOR TREATING SUGAR DIABETES | |
| UA115684C2 (en) | PHARMACEUTICAL FOR ORAL APPLICATION CONTAINING DEXTETROPROPHENE AND Tramadol | |
| RU2013121820A (en) | COMBINED MEDICINE FOR THE ELIMINATION OF SYMPTOMS AND TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA | |
| RU2011109432A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF A HEART OF A LONG-TERM ACTION | |
| RU2013131840A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF OBESITY DISORDERS AND METHOD OF TREATMENT AND / OR PREVENTION OF OBESITY DISORDERS | |
| RU2013157796A (en) | PHARMACEUTICAL COMPOSITION BASED ON MOXIFLOXACIN | |
| RU2011104563A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ARTERIAL HYPERTENSION AND CONSTANT HEART FAILURE AND METHOD FOR ITS PRODUCTION | |
| RU2021123106A (en) | COMPOSITIONS CONTAINING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR MODULATORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20151102 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20170120 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20181016 |
|
| QB4A | Licence on use of patent |
Free format text: LICENCE FORMERLY AGREED ON 20181016 Effective date: 20181016 |